Vera Therapeutics (VERA) Cash from Operations (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Cash from Operations data on file, last reported at 106500000.0 in Q1 2026.

• Quarterly Cash from Operations fell 95.75% year-over-year to 106500000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 293198000.0 (down 88.85% YoY) and the FY2025 annual result came in at 241104000.0, down 79.02% from the prior year.
• Cash from Operations eased to 106500000.0 in Q1 2026, from 69994000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 8981000.0 in Q1 2022 to a low of 106500000.0 in Q1 2026.
• A 5-year average of 37768235.29 and a median of 26292000.0 in 2023 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2022 — Cash from Operations tumbled 235.89% — and 2023, when it advanced 6.63%.
• Tracing VERA's Cash from Operations over 5 years: stood at 21162000.0 in 2022, then fell by 18.82% to 25144000.0 in 2023, then tumbled by 55.83% to 39182000.0 in 2024, then plunged by 78.64% to 69994000.0 in 2025, then sank by 52.16% to 106500000.0 in 2026.
• The last three Cash from Operations figures came in at 106500000.0 (Q1 2026), 69994000.0 (Q4 2025), and 61906000.0 (Q3 2025), per Business Quant data.